On the stock market since 2020, it operates in the world of health and science. It has 30 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $30.1M in the vault; even if every debt were paid off, $29.7M would remain.
Over the last 12 months, company executives reported 12 buys and 7 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $9.00 — 350% above today’s price.
A loss of $6.6M against $0 in annual sales.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 22/100. For a turnaround signal, the stock first needs to close the gap with the market.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 46/100.
On our five-subject report card, NBP sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NBP is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (54/100) says the stock isn’t cheap.